Hybrid tumor DY01 of monoclonal antibody of human ubiquitin-conjugating enzyme UbcH10, and monoclonal antibody

Abstract

The invention discloses a hybrid tumor DY01 of a monoclonal antibody of a human ubiquitin-conjugating enzyme UbcH10, and the monoclonal antibody. The hybrid tumor DY01 of the monoclonal antibody of the human ubiquitin-conjugating enzyme UbcH10 is collected in China General Microbiological Culture Collection Center on Nov. 19, 2010 with the collection number of CGMCC No.4334. The monoclonal antibody generated can specifically combine the natural human ubiquitin-conjugating enzyme UbcH10. The antibody can be used for enzyme-linked immuno sorbent assay (ELISA), western-blot, cell immunofluorescence and immunohistochemical dyeing study of clinical tissue specimens. Meanwhile, the antibody can be used for preparing an immunodetection reagent for detecting the expression condition of the human ubiquitin-conjugating enzyme UbcH10 in laboratories and clinically.

Description

[0001] technical field [0002] The invention relates to the field of cell engineering, in particular to a human ubiquitin coupling enzyme UbcH10 monoclonal antibody hybridoma DY01 and the monoclonal antibody. Background technique [0003] Early diagnosis of tumors is of great significance to the treatment and prognosis of cancer patients. Currently, commonly used clinical tumor markers such as alpha-fetoprotein AFP and CEA lack sufficient detection specificity and sensitivity. Therefore, it is necessary to select more specific detection targets. point. [0004] There are two main pathways for intracellular protein degradation: the proteasomal pathway and the lysosomal pathway. Most short-lived proteins are degraded by the proteasomal pathway. Most proteins degraded by the proteasome pathway are first ubiquitinated and then degraded by the proteasome. Therefore, this pathway is also called the ubiquitin-proteasome pathway (ubiquitin proteasome pathway; UPP). UbcH10 b...

AI Technical Summary

Problems solved by technology

[0009] At present, there is no localized human ubiquitin-conjugating enzyme UbcH10 antibody. Some foreign companies have antibody products that can detect UbcH10, but most of them are polyclonal antibodies. For example, Abnova Corporation is a mouse-derived polyclonal antibody, and Boston Biochem , Inc. and Millipore are rabbit-derived polyclonal antibodies, Everest Biotech, Novus Biologicals, Raybiotech, Inc., and IMGENEX are goat-derived polyclonal antibodies, and Santa Cruz Biotechnology, Inc. has two different antibodies against UbcH10 Fragment antibody products, only Novus Biologicals has mouse-derived monoclonal antibody products against human ubiquitin conjugating enzyme E2C, but its immunogenic protein amino acid sequence is AAH50736 including 180 amino acids, and its monoclonal antibody subtype is IgG3b1 type, For ELISA and Western only

At the same time, the price of foreign antibodies is usually relatively expensive, which also limits the validation of the protein as a clinical target and research on its function

Images